Biomedical
A Gene Therapy for Hereditary Nonpolyposis Colorectal Cancer using CRISPR-Cas9 Nickase
Peer Reviewed
Abstract
Hereditary non-polyposis colorectal cancer (HNPCC) is an inherited disorder characterized by an increased risk of developing colorectal cancer before age 50. HNPCC is predominantly caused by genetic mutations in MLH1 and MSH2, which are involved in DNA mismatch repair. Current standard practice is to perform prophylactic colectomy, resulting in debilitating aftereffects for life. Though the genetic cause of HNPCC is well-known, there are currently no available treatments that target these mutations. Herein we describe a novel treatment protocol using a CRISPR-Cas9n-based genetic therapy to restore DNA mismatch repair. First, gRNA and template DNA targeting the most prevalent mutation clusters in MLH1 and MSH2 as well as CRISPR-Cas9n elements will be packaged into an integrase-deficient lentiviral vector. Then, the viral vector will be used to transduce human colonic tumor-derived organoids as well as administered systemically in mouse models of HNPCC. Mice will be monitored clinically and for signs of disease progression. At termination, colonic tissue will be harvested and analyzed for restoration of the wild-type MLH1 and MSH2 sequence and biochemical markers of HNPCC. This protocol offers an alternative strategy using CRISPR-Cas9n-based gene therapy to prevent tumor formation in patients, avoid morbid surgery, and significantly improve quality of life.
Key Questions
What is Hereditary Nonpolyposis Colorectal Cancer (HNPCC)?
HNPCC, also known as Lynch syndrome, is an inherited disorder characterized by an increased risk of developing colorectal cancer before age 50. It is predominantly caused by genetic mutations in MLH1 and MSH2, which are involved in DNA mismatch repair.
What is the current standard treatment for HNPCC?
The current standard practice is to perform prophylactic colectomy, resulting in lifelong debilitating aftereffects. Although the genetic cause of HNPCC is well-known, there are currently no available treatments that target these mutations.
What novel treatment protocol is proposed in the article?
The article describes a novel treatment protocol using a CRISPR-Cas9n-based genetic therapy to restore DNA mismatch repair. This involves packaging gRNA and template DNA targeting prevalent mutation clusters in MLH1 and MSH2, along with CRISPR-Cas9n elements, into an integrase-deficient lentiviral vector. The viral vector will then be used to transduce human colonic tumor-derived organoids and administered systemically in mouse models of HNPCC.
